Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics announced promising preliminary results from its Phase 2 trial of (Z)-endoxifen, showing significant efficacy and tolerability in breast cancer treatment. The findings will be presented at the RISE UP Breast Cancer Conference.
October 31, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics' (Z)-endoxifen met primary endpoints in a Phase 2 trial, showing promising results in breast cancer treatment. The drug was well tolerated and effective in reducing key biomarkers.
The successful meeting of primary endpoints in a Phase 2 trial is a significant milestone for Atossa Therapeutics, indicating potential for (Z)-endoxifen in breast cancer treatment. This positive development is likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100